日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma

晚期黑色素瘤患者接受纳武利尤单抗联合伊匹木单抗治疗的最终10年疗效

Wolchok, Jedd D; Chiarion-Sileni, Vanna; Rutkowski, Piotr; Cowey, C Lance; Schadendorf, Dirk; Wagstaff, John; Queirolo, Paola; Dummer, Reinhard; Butler, Marcus O; Hill, Andrew G; Postow, Michael A; Gaudy-Marqueste, Caroline; Medina, Theresa; Lao, Christopher D; Walker, John; Márquez-Rodas, Iván; Haanen, John B A G; Guidoboni, Massimo; Maio, Michele; Schöffski, Patrick; Carlino, Matteo S; Sandhu, Shahneen; Lebbé, Céleste; Ascierto, Paolo A; Long, Georgina V; Ritchings, Corey; Nassar, Ayman; Askelson, Margarita; Benito, Melanie Pe; Wang, Wenjia; Hodi, F Stephen; Larkin, James

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

皮肤黑色素瘤:ESMO临床实践指南(诊断、治疗和随访)

Amaral, T; Ottaviano, M; Arance, A; Blank, C; Chiarion-Sileni, V; Donia, M; Dummer, R; Garbe, C; Gershenwald, J E; Gogas, H; Guckenberger, M; Haanen, J; Hamid, O; Hauschild, A; Höller, C; Lebbé, C; Lee, R J; Long, G V; Lorigan, P; Muñoz Couselo, E; Nathan, P; Robert, C; Romano, E; Schadendorf, D; Sondak, V; Suijkerbuijk, K P M; van Akkooi, A C J; Michielin, O; Ascierto, P A

Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020

RELATIVITY-020 研究显示,既往和一线免疫疗法对黑色素瘤患者基线免疫生物标志物的影响以及对纳武利尤单抗和瑞拉利单抗联合治疗的肿瘤微环境调节的影响

Ascierto, Paolo A; Tang, Hao; Dolfi, Sonia; Nyakas, Marta; Marie Svane, Inge; Muñoz-Couselo, Eva; Grob, Jean Jacques; Gomez-Roca, Carlos Alberto; Chiarion-Sileni, Vanna; Peltola, Katriina; Larkin, James; Melero, Ignacio; Callahan, Margaret; Dummer, Reinhard; Djidel, Patrick; Warad, Deepti; Reusser-Wolf, Diane; Lipson, Evan J; Garnett-Benson, Charlie

Real-world multicentre observational study of effectiveness and toxicity in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab

一项真实世界多中心观察性研究,旨在评估西米普利单抗治疗晚期皮肤鳞状细胞癌患者的疗效和毒性

Faoro, L; Salizzato, V; Coppola, M; Carpanese, D; Fabozzi, A; Tondulli, L; Marconcini, R; Spagnolo, F; Del Bianco, P; Chiarion-Sileni, V; Piccin, L

A model workflow for microfluidic enrichment and genetic analysis of circulating melanoma cells

用于循环黑色素瘤细胞微流控富集和基因分析的模型工作流程

Cristina Poggiana # ,Alessandro Francesco Piazza # ,Cristina Catoni ,Ilaria Gallingani ,Luisa Piccin ,Stefania Pellegrini ,Vittorio Aneloni ,Valentina Salizzato ,Jacopo Pigozzo ,Alessio Fabozzi ,Antonella Facchinetti ,Chiara Menin ,Paolo Del Fiore ,Simone Mocellin ,Vanna Chiarion-Sileni ,Antonio Rosato # ,Maria Chiara Scaini #

Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

出版商更正:辅助性纳武利尤单抗治疗切除术后的 IIB/C 期黑色素瘤:来自随机、3 期 CheckMate 76K 试验的主要结果

Kirkwood, John M; Del Vecchio, Michele; Weber, Jeffrey; Hoeller, Christoph; Grob, Jean-Jacques; Mohr, Peter; Loquai, Carmen; Dutriaux, Caroline; Chiarion-Sileni, Vanna; Mackiewicz, Jacek; Rutkowski, Piotr; Arenberger, Petr; Quereux, Gaelle; Meniawy, Tarek M; Ascierto, Paolo A; Menzies, Alexander M; Durani, Piyush; Lobo, Maurice; Campigotto, Federico; Gastman, Brian; Long, Georgina V

Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

作者更正:辅助性纳武利尤单抗治疗切除术后的 IIB/C 期黑色素瘤:来自随机、3 期 CheckMate 76K 试验的主要结果

Kirkwood, John M; Del Vecchio, Michele; Weber, Jeffrey; Hoeller, Christoph; Grob, Jean-Jacques; Mohr, Peter; Loquai, Carmen; Dutriaux, Caroline; Chiarion-Sileni, Vanna; Mackiewicz, Jacek; Rutkowski, Piotr; Arenberger, Petr; Quereux, Gaelle; Meniawy, Tarek M; Ascierto, Paolo A; Menzies, Alexander M; Durani, Piyush; Lobo, Maurice; Campigotto, Federico; Gastman, Brian; Long, Georgina V

Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study

帕博利珠单抗与安慰剂作为切除术后 IIB 或 IIC 期黑色素瘤辅助治疗的疗效比较:KEYNOTE-716 III 期研究的远处转移无进展生存期最终分析

Luke, Jason J; Ascierto, Paolo A; Khattak, Muhammad A; de la Cruz Merino, Luis; Del Vecchio, Michele; Rutkowski, Piotr; Spagnolo, Francesco; Mackiewicz, Jacek; Chiarion-Sileni, Vanna; Kirkwood, John M; Robert, Caroline; Grob, Jean-Jacques; de Galitiis, Federica; Schadendorf, Dirk; Carlino, Matteo S; Wu, Xi Lawrence; Fukunaga-Kalabis, Mizuho; Krepler, Clemens; Eggermont, Alexander M M; Long, Georgina V

Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238

CheckMate 238 研究中接受辅助检查点抑制剂治疗的黑色素瘤切除术后复发患者接受全身治疗的疗效

Weber, Jeffrey; Del Vecchio, Michele; Mandalá, Mario; Gogas, Helen; Arance, Ana M; Dalle, Stephane; Cowey, C Lance; Schenker, Michael; Grob, Jean-Jacques; Chiarion-Sileni, Vanna; Márquez-Rodas, Iván; Butler, Marcus O; Di Giacomo, Anna Maria; de la Cruz-Merino, Luis; Arenberger, Petr; Atkinson, Victoria; Hill, Andrew; Fecher, Leslie A; Millward, Michael; Khushalani, Nikhil I; Queirolo, Paola; Long, Georgina V; Lobo, Maurice; Askelson, Margarita; Ascierto, Paolo A; Larkin, James

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial

帕博利珠单抗与安慰剂作为切除术后 IIB 或 IIC 期黑色素瘤辅助治疗的疗效比较:来自随机、双盲、3 期 KEYNOTE-716 试验的组织病理学亚组结果

Schadendorf, Dirk; Luke, Jason John; Ascierto, Paolo A; Long, Georgina V; Rutkowski, Piotr; Khattak, Adnan; Del Vecchio, Michele; de la Cruz-Merino, Luis; Mackiewicz, Jacek; Sileni, Vanna Chiarion; Kirkwood, John M; Robert, Caroline; Grob, Jean-Jacques; Dummer, Reinhard; Carlino, Matteo S; Zhao, Yujie; Kalabis, Mizuho; Krepler, Clemens; Eggermont, Alexander; Scolyer, Richard A